hypericin has been researched along with Neoplasms in 41 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Excerpt | Relevance | Reference |
---|---|---|
"To study whether formulation influences biodistribution, necrosis avidity and tumoricidal effects of the radioiodinated hypericin, a necrosis avid agent for a dual-targeting anticancer radiotherapy." | 7.80 | Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. ( Alpizar, YA; Bauwens, M; Chen, F; Cona, MM; de Witte, P; Feng, Y; Li, J; Ni, Y; Oyen, R; Sun, Z; Talavera, K; Verbruggen, A; Zhang, J, 2014) |
"In conclusion, NTRT improved the anticancer efficacy of VDT in rabbits with VX2 tumors." | 5.42 | Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. ( Chen, F; Dai, X; Li, Y; Ni, Y; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015) |
"To study whether formulation influences biodistribution, necrosis avidity and tumoricidal effects of the radioiodinated hypericin, a necrosis avid agent for a dual-targeting anticancer radiotherapy." | 3.80 | Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. ( Alpizar, YA; Bauwens, M; Chen, F; Cona, MM; de Witte, P; Feng, Y; Li, J; Ni, Y; Oyen, R; Sun, Z; Talavera, K; Verbruggen, A; Zhang, J, 2014) |
"Hypericin is a prominent secondary metabolite mainly existing in genus Hypericum." | 3.01 | Hypericin: A natural anthraquinone as promising therapeutic agent. ( Ding, K; He, J; Li, XX; Pan, XG; Wu, JJ; Xia, CY; Xu, JK; Zhang, J; Zhang, WK, 2023) |
"Hypericin is a polycyclic aromatic naphthodianthrone that occurs naturally." | 2.72 | Hypericin-mediated photodynamic therapy for the treatment of cancer: a review. ( Cruz, LJ; Dong, X; Fu, J; Gu, Z; Hao, Y; He, Y; Ni, J; Qu, C; Yin, X; You, L; Yu, Z; Zeng, Y; Zhang, Z, 2021) |
"Hypericin (HY) is an interesting photosensitizer with dark activity and photodynamic therapy (PDT) effects via p53-independent pathway." | 2.44 | Potentiation of the photodynamic action of hypericin. ( Heng, PW; Olivo, M; Saw, CL, 2008) |
"Hypericin is a naturally occurring substance found in the common St." | 2.43 | Hypericin--the facts about a controversial agent. ( Alth, G; Burner, U; Grünberger, W; Kubin, A; Wierrani, F, 2005) |
"Hypericin is a naturally occurring secondary metabolite in plants of the Hypericum genus, with Hypericum perforatum (St." | 2.43 | Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. ( Kiesslich, T; Krammer, B; Plaetzer, K, 2006) |
"Hypericin aggregates were confirmed by absorption spectra typical of aggregated hypericin and by its short fluorescence lifetime." | 1.91 | Effective transport of aggregated hypericin encapsulated in SBA-15 nanoporous silica particles for photodynamic therapy of cancer cells. ( Almáši, M; Benziane, A; Girman, V; Huntošová, V; Miklóšová, M; Pevná, V; Vámosi, G; Zauška, Ľ; Zeleňák, V, 2023) |
" A marked decrease in the glutathione level of a majority of cells was observed after more toxic combination treatment." | 1.42 | Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status. ( Fedoročko, P; Jendželovská, Z; Jendželovský, R; Kovaľ, J; Kuchárová, B; Mikeš, J; Mikešová, L; Vargová, J, 2015) |
"In conclusion, NTRT improved the anticancer efficacy of VDT in rabbits with VX2 tumors." | 1.42 | Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. ( Chen, F; Dai, X; Li, Y; Ni, Y; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015) |
"Moreover, we found that a subset of cancer patients of various cancer-types indeed possessed CALRlow or CRTlow-tumours." | 1.42 | Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. ( Agostinis, P; de Witte, P; Elsen, S; Garg, AD; Krysko, DV; Vandenabeele, P, 2015) |
"Autophagy-attenuated cancer cells displayed enhanced ecto-CALR induction following Hyp-PDT, which strongly correlated with their inability to clear oxidatively damaged proteins." | 1.39 | ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. ( Agostinis, P; Dudek, AM; Ferreira, GB; Garg, AD; Krysko, DV; Mathieu, C; Vandenabeele, P; Verfaillie, T, 2013) |
"Hypericin was conjugated to biotin-ethylenediamine in a straightforward coupling method using n-hydroxysuccinimide and dicyclohexylcarbodiimide." | 1.38 | Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy. ( Bauwens, M; Bormans, G; de Witte, P; Marysael, T; Ni, Y; Rozenski, J, 2012) |
"Here, we show that when cancer cells are treated with hypericin-based PDT (Hyp-PDT), they surface-expose both HSP70 and calreticulin (CRT)." | 1.38 | Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. ( Agostinis, P; Garg, AD; Krysko, DV; Vandenabeele, P, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (21.95) | 29.6817 |
2010's | 19 (46.34) | 24.3611 |
2020's | 13 (31.71) | 2.80 |
Authors | Studies |
---|---|
Zhang, L | 1 |
Zhang, G | 1 |
Xu, S | 1 |
Song, Y | 1 |
Liang, R | 1 |
Wong, KH | 1 |
Yang, Y | 1 |
Duan, Y | 1 |
Chen, M | 1 |
Wu, JJ | 1 |
Zhang, J | 3 |
Xia, CY | 1 |
Ding, K | 1 |
Li, XX | 1 |
Pan, XG | 1 |
Xu, JK | 1 |
He, J | 1 |
Zhang, WK | 1 |
Buľková, V | 1 |
Vargová, J | 3 |
Babinčák, M | 1 |
Jendželovský, R | 3 |
Zdráhal, Z | 1 |
Roudnický, P | 1 |
Košuth, J | 1 |
Fedoročko, P | 3 |
de Morais, FAP | 1 |
Balbinot, RB | 1 |
Bakoshi, ABK | 1 |
Lazarin-Bidoia, D | 1 |
da Silva Souza Campanholi, K | 1 |
da Silva Junior, RC | 1 |
Gonçalves, RS | 1 |
Ueda-Nakamura, T | 1 |
de Oliveira Silva, S | 1 |
Caetano, W | 1 |
Nakamura, CV | 1 |
Pevná, V | 1 |
Zauška, Ľ | 1 |
Benziane, A | 1 |
Vámosi, G | 1 |
Girman, V | 1 |
Miklóšová, M | 1 |
Zeleňák, V | 1 |
Huntošová, V | 2 |
Almáši, M | 1 |
Borghi-Pangoni, FB | 1 |
Junqueira, MV | 1 |
Bruschi, ML | 1 |
Ke, Z | 1 |
Xie, A | 1 |
Chen, J | 2 |
Zou, Z | 1 |
Shen, L | 1 |
Dai, Y | 1 |
Zou, D | 1 |
Han, X | 1 |
Taratula, O | 2 |
Xu, K | 2 |
St Lorenz, A | 1 |
Moses, A | 1 |
Jahangiri, Y | 1 |
Yu, G | 1 |
Farsad, K | 1 |
Teng, X | 1 |
Li, F | 1 |
Lu, C | 1 |
Li, B | 1 |
Verebová, V | 1 |
Beneš, J | 1 |
Staničová, J | 1 |
Li, Y | 2 |
Wang, S | 1 |
Jiang, X | 1 |
Wang, X | 1 |
Zhou, X | 1 |
Wan, L | 1 |
Zhao, H | 1 |
Zhou, Z | 1 |
Gao, L | 1 |
Huang, G | 1 |
Ni, Y | 6 |
He, X | 1 |
Dong, X | 1 |
Zeng, Y | 1 |
Zhang, Z | 1 |
Fu, J | 1 |
You, L | 1 |
He, Y | 1 |
Hao, Y | 1 |
Gu, Z | 1 |
Yu, Z | 1 |
Qu, C | 1 |
Yin, X | 1 |
Ni, J | 1 |
Cruz, LJ | 1 |
Mikeš, J | 2 |
Mikešová, L | 2 |
Kuchárová, B | 2 |
Čulka, Ľ | 1 |
Fedr, R | 1 |
Remšík, J | 1 |
Souček, K | 1 |
Kozubík, A | 1 |
Geng, C | 1 |
Zhang, Y | 1 |
Hidru, TH | 1 |
Zhi, L | 1 |
Tao, M | 1 |
Zou, L | 1 |
Chen, C | 1 |
Li, H | 1 |
Liu, Y | 2 |
Garg, AD | 4 |
Dudek, AM | 1 |
Ferreira, GB | 1 |
Verfaillie, T | 1 |
Vandenabeele, P | 3 |
Krysko, DV | 3 |
Mathieu, C | 1 |
Agostinis, P | 7 |
Cona, MM | 2 |
Alpizar, YA | 1 |
Li, J | 1 |
Bauwens, M | 2 |
Feng, Y | 2 |
Sun, Z | 2 |
Chen, F | 2 |
Talavera, K | 1 |
de Witte, P | 5 |
Verbruggen, A | 2 |
Oyen, R | 2 |
Barras, A | 1 |
Boussekey, L | 1 |
Courtade, E | 1 |
Boukherroub, R | 1 |
Koole, M | 1 |
Jendželovská, Z | 1 |
Kovaľ, J | 1 |
Shao, H | 1 |
Dai, X | 1 |
Elsen, S | 1 |
Saw, CL | 1 |
Heng, PW | 1 |
Olivo, M | 5 |
Karioti, A | 1 |
Bilia, AR | 1 |
Ni, G | 1 |
Chi, M | 1 |
Marysael, T | 2 |
Lerut, E | 1 |
Barliya, T | 1 |
Mandel, M | 1 |
Livnat, T | 1 |
Weinberger, D | 1 |
Lavie, G | 1 |
Fu, CY | 1 |
Raghavan, V | 1 |
Lau, WK | 1 |
Bormans, G | 1 |
Rozenski, J | 1 |
Krammer, B | 2 |
Verwanger, T | 1 |
Buzova, D | 1 |
Petrovajova, D | 1 |
Kasak, P | 1 |
Nadova, Z | 1 |
Jancura, D | 1 |
Sureau, F | 1 |
Miskovsky, P | 1 |
Ali, SM | 1 |
Piette, J | 2 |
Volanti, C | 1 |
Vantieghem, A | 2 |
Matroule, JY | 2 |
Habraken, Y | 1 |
Chin, W | 2 |
Lau, W | 1 |
Lay, SL | 1 |
Wei, KK | 1 |
Kubin, A | 1 |
Wierrani, F | 1 |
Burner, U | 1 |
Alth, G | 1 |
Grünberger, W | 1 |
Kiesslich, T | 1 |
Plaetzer, K | 1 |
Kocanova, S | 1 |
Buytaert, E | 1 |
Golab, J | 1 |
Merlevede, W | 1 |
de Witte, PA | 1 |
15 reviews available for hypericin and Neoplasms
Article | Year |
---|---|
Recent advances of quinones as a privileged structure in drug discovery.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cell Line, Tumor; Communicable Diseases; Drug | 2021 |
Hypericin: A natural anthraquinone as promising therapeutic agent.
Topics: Anthracenes; Anthraquinones; Humans; Neoplasms; Photochemotherapy | 2023 |
Biophysical Characterization and Anticancer Activities of Photosensitive Phytoanthraquinones Represented by Hypericin and Its Model Compounds.
Topics: Animals; Anthracenes; Anthraquinones; Antineoplastic Agents; Humans; Neoplasms; Perylene; Photochemo | 2020 |
Hypericin-mediated photodynamic therapy for the treatment of cancer: a review.
Topics: Anthracenes; Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasms; Perylene; Photoch | 2021 |
Sonodynamic therapy: A potential treatment for atherosclerosis.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Atherosclerosis; Berberine; Cell Death; Chal | 2018 |
ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses.
Topics: Animals; Anthracenes; Autophagy; Cell Death; Endoplasmic Reticulum Stress; Humans; Immune System Phe | 2014 |
Potentiation of the photodynamic action of hypericin.
Topics: Adjuvants, Pharmaceutic; Animals; Anthracenes; Combined Modality Therapy; Humans; Neoplasms; Perylen | 2008 |
Hypericins as potential leads for new therapeutics.
Topics: Anthracenes; Anti-Infective Agents; Antidepressive Agents; Cell Survival; Humans; Hypericum; Neoplas | 2010 |
New frontier in hypericin-mediated diagnosis of cancer with current optical technologies.
Topics: Anthracenes; Diagnostic Imaging; Fluorescence; Humans; Neoplasms; Perylene; Photochemotherapy; Photo | 2012 |
Molecular response to hypericin-induced photodamage.
Topics: Animals; Anthracenes; Antineoplastic Agents; Humans; Neoplasms; Perylene; Photochemotherapy; Photose | 2012 |
Cell death and growth arrest in response to photodynamic therapy with membrane-bound photosensitizers.
Topics: Animals; Anthracenes; Apoptosis; Cell Division; Humans; Mitochondria; Neoplasms; Perylene; Photochem | 2003 |
Hypericin--the facts about a controversial agent.
Topics: Animals; Anthracenes; Austria; Cell Death; Humans; Molecular Structure; Neoplasms; Perylene; Photoch | 2005 |
Perylenequinones in photodynamic therapy: cellular versus vascular response.
Topics: Animals; Anthracenes; Apoptosis; Blood Vessels; Humans; Neoplasms; Perylene; Phenol; Photochemothera | 2006 |
Cellular mechanisms and prospective applications of hypericin in photodynamic therapy.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Humans; Hydrogen-Io | 2006 |
Hypericin in cancer treatment: more light on the way.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Cytochrome c Group; HeLa Cells; Humans; Hypericum; Mi | 2002 |
26 other studies available for hypericin and Neoplasms
Article | Year |
---|---|
ROS-responsive dexamethasone micelles normalize the tumor microenvironment enhancing hypericin in cancer photodynamic therapy.
Topics: Anthracenes; Cell Line, Tumor; Dexamethasone; Endothelial Cells; Micelles; Neoplasms; Perylene; Phot | 2022 |
New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Basic Helix-Loop-Helix Transcription Factor | 2023 |
Advanced theranostic nanoplatforms for hypericin delivery in the cancer treatment.
Topics: Anthracenes; Caco-2 Cells; Humans; Lipids; Neoplasms; Perylene; Photochemotherapy; Polymers; Precisi | 2023 |
Effective transport of aggregated hypericin encapsulated in SBA-15 nanoporous silica particles for photodynamic therapy of cancer cells.
Topics: Anthracenes; Nanopores; Neoplasms; Perylene; Photochemotherapy; Photosensitizing Agents; Silicon Dio | 2023 |
Physicochemical stability of bioadhesive thermoresponsive platforms for methylene blue and hypericin delivery in photodynamic therapy.
Topics: Acrylates; Adhesives; Anthracenes; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberati | 2020 |
Naturally available hypericin undergoes electron transfer for type I photodynamic and photothermal synergistic therapy.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Electrons; Female; HeLa Cells; Humans | 2020 |
Biodegradable Hypericin-Containing Nanoparticles for Necrosis Targeting and Fluorescence Imaging.
Topics: Animals; Anthracenes; Cell Line, Tumor; Female; Humans; Mice; Nanoparticles; Necrosis; Neoplasms; Op | 2020 |
Carbon dot-assisted luminescence of singlet oxygen: the generation dynamics but not the cumulative amount of singlet oxygen is responsible for the photodynamic therapy efficacy.
Topics: Animals; Anthracenes; Antineoplastic Agents; Carbon; Female; HeLa Cells; Humans; Imidazoles; Lumines | 2020 |
Preparation and validation of cyclodextrin-based excipients for radioiodinated hypericin applied in a targeted cancer radiotherapy.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Anthracenes; Cyclodextrins; Excipients; Humans; Neoplasms; Peryle | 2021 |
Hypericin affects cancer side populations via competitive inhibition of BCRP.
Topics: Aldehyde Dehydrogenase; Animals; Anthracenes; ATP Binding Cassette Transporter, Subfamily B, Member | 2018 |
ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death.
Topics: Adenosine Triphosphate; Anthracenes; Autophagy; Autophagy-Related Protein 5; Calreticulin; CD4-Posit | 2013 |
Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.
Topics: Animals; Anthracenes; Antineoplastic Agents; Chemistry, Pharmaceutical; Dimethyl Sulfoxide; Iodine R | 2014 |
Hypericin-loaded lipid nanocapsules for photodynamic cancer therapy in vitro.
Topics: Anthracenes; Cell Line; Cell Survival; Drug Carriers; HeLa Cells; Humans; Hypericum; Light; Lipids; | 2013 |
Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic.
Topics: Animals; Anthracenes; Female; Humans; Iodine Radioisotopes; Male; Neoplasms; Perylene; Radiation Dos | 2014 |
Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status.
Topics: Anthracenes; ATP-Binding Cassette Transporters; Caspase 3; Cell Death; Cell Line, Tumor; Drug Synerg | 2015 |
Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.
Topics: Animals; Anthracenes; Autoradiography; Disease Models, Animal; Iodine Radioisotopes; Necrosis; Neopl | 2015 |
Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Calreticulin; Cancer Vacc | 2015 |
The possible use of hypericin to overcome drug resistance in cancer treatment.
Topics: Anthracenes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochr | 2011 |
Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Mice; Mice, Inbred C3H; Necrosis; Neo | 2011 |
Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy.
Topics: Anthracenes; Antineoplastic Agents; Blotting, Western; Cathepsin B; Cell Hypoxia; Cell Line; Cell Li | 2011 |
Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy.
Topics: Animals; Anthracenes; Antineoplastic Agents; Avidin; Biotin; Biotinylation; Cell Line, Tumor; Contra | 2012 |
Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin.
Topics: Animals; Anthracenes; Anthracyclines; Apoptosis; Cell Line; Dendritic Cells; Hematoporphyrin Photora | 2012 |
Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells.
Topics: Anthracenes; Cell Line, Tumor; Dextrans; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interact | 2012 |
Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Colonic Neoplasms; Cytochrome c Group; Humans; Intrac | 2002 |
Photodynamic-induced vascular damage of the chick chorioallantoic membrane model using perylenequinones.
Topics: Animals; Anthracenes; Blood Vessels; Chickens; Chorioallantoic Membrane; Neoplasms; Perylene; Photoc | 2004 |
Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Enzyme Induction; Enzyme Inhibitors; Heme Oxygenase-1; Hum | 2007 |